Back to results
US 2019/0055317 A1Published application
TREATMENT WITH ANTI-ErbB2 ANTIBODIES
AssigneeGenentech, Inc.
InventorsSharon A. Baughman, Steven Shak
Life of this patent
Estimating the term…
Abstract
The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
Claims10
A method for the treatment of a human patient diagnosed with breast cancer characterized by overexpression of ErbB2, comprising the steps of administering to the patient an initial dose of 8 mg/kg of the anti-ErbB2 antibody;
- and administering to the patient a plurality of subsequent doses of the antibody in an amount that is 6 mg/kg wherein the doses are separated in time from each other by three weeks.
Dependencies are inferred from the claim text.